Novartis turns to Beigene for a PD-1 blocker
The pharma giant resorts to deal-making for a much-needed late-stage IO asset, leaving its own PD-1 agent out in the cold.
UK asserts its independence with first Covid-19 vaccine nod
The UK’s swift authorisation of Biontech and Pfizer’s Covid-19 shot has attracted both praise and concern.
CTOS 2020 – Karyopharm seeks a solid tumour Seal of approval
Despite the lack of an overall survival benefit the Seal study gives Karyopharm enough to file for Xpovio’s first solid tumour use.
Bristol scores early
The first of several perioperative Opdivo trials is said to read out positively, reminding the markets of such settings’ importance.
Esmo 2020 – double win complicates the gastric cancer picture
Bristol Myers Squibb and Merck & Co hail front-line successes, but histology and biomarker status will remain live issues for doctors.
